Renate Starr Selected Research

Chimeric Antigen Receptors

3/2024	Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.
1/2024	Targeting Wnt signaling for improved glioma immunotherapy.
1/2023	Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells.
1/2022	Engineered IL13 variants direct specificity of IL13Rα2-targeted CAR T cell therapy.
1/2022	Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma.
1/2022	Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma.
1/2022	Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells.
1/2021	CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies.
12/2020	Systemic Anti-PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid.
1/2020	Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Renate Starr Research Topics

Disease

21	Neoplasms (Cancer) 03/2024 - 09/2007
15	Glioblastoma (Glioblastoma Multiforme) 01/2024 - 04/2010
10	Glioma (Gliomas) 03/2024 - 12/2009
5	Brain Neoplasms (Brain Tumor) 12/2020 - 01/2013
1	Necrosis 01/2022
1	Hematologic Neoplasms (Hematological Malignancy) 01/2018
1	Encephalitis (Encephalitis, Rasmussen) 09/2015
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2013
1	Melanoma (Melanoma, Malignant) 09/2007
1	Lymphoma (Lymphomas) 09/2007
1	Neuroblastoma 09/2007

Drug/Important Bio-Agent (IBA)

18	Chimeric Antigen ReceptorsIBA 03/2024 - 10/2013
11	AntigensIBA 01/2024 - 12/2009
5	CytokinesIBA 03/2024 - 12/2009
5	Interleukin-13IBA 01/2023 - 04/2012
3	Interleukin-13 Receptors (Interleukin 13 Receptor)IBA 01/2018 - 01/2013
2	LigandsIBA 01/2023 - 01/2022
2	Peptides (Polypeptides)IBA 01/2022 - 01/2020
2	Monoclonal AntibodiesIBA 01/2022 - 01/2014
2	Therapeutic UsesIBA 01/2018 - 09/2007
1	Biomarkers (Surrogate Marker)IBA 03/2024
1	CateninsIBA 01/2024
1	SurvivinIBA 01/2024
1	ICG 001IBA 01/2024
1	CREB-Binding ProteinIBA 01/2024
1	Cytostatic AgentsIBA 01/2024
1	SteroidsIBA 01/2022
1	aldesleukin (Proleukin)FDA Link 01/2022
1	ImmunosorbentsIBA 12/2020
1	EnzymesIBA 12/2020
1	pembrolizumabIBA 12/2020
1	ChlorotoxinIBA 01/2020
1	antiglomerular basement membrane antibodyIBA 01/2020
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2018
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2018
1	Cell Surface ReceptorsIBA 01/2014
1	berbamine (penduline)IBA 01/2014
1	AntibodiesIBA 01/2014
1	IL13-zetakineIBA 01/2014
1	Interleukin-4 (Interleukin 4)IBA 01/2014
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2014
1	Interleukin-13 Receptor alpha2 SubunitIBA 01/2014
1	Sorafenib (BAY 43-9006)FDA Link 04/2010
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 12/2009
1	PerforinIBA 12/2009
1	Firefly LuciferasesIBA 09/2007
1	ChemokinesIBA 09/2007

Therapy/Procedure

9	Therapeutics 03/2024 - 12/2009
6	Immunotherapy 01/2024 - 01/2013
2	Drug Therapy (Chemotherapy) 01/2024 - 12/2009
1	Decompression 01/2024
1	Aftercare (After-Treatment) 01/2024
1	Intraventricular Infusions 01/2018
1	Intravenous Administration 01/2018
1	Radiotherapy 12/2009